We are hosting our 27th German Investment Seminar in New York from 13 to 15 January 2025. In total, 66 companies are participating. Below, we provide some of our initial feedback on the companies, which were present on day one. Among these companies which were presented during the first day, we notably highlight a positive feedback on BASF, Fresenius Medical Care and Merck AG. We also keep our positive ratings on stocks like Commerzbank, Deutsche Telekom and Schaeffler. We maintain our underperf...
Swiss-based Accelleron was formed from the spin-off of ABB’s highly profitable turbocharger division in 2022. We view the share as a promising investment on 1/ market leadership in an attractive niche, 2/ about ~40% ROCE, 3/ conversion of ~80% of EBITDA into cash, leading to fast deleveraging, and a solid base for shareholder remuneration (75% pay out), and 4/ strong long-term visibility linked to a ~75% service share, the bulk of which is recurring. Despite an already strong stock pe...
>Life Sciences – the turnaround for Process solutions - While there is still some residual headwind related to destocking and the changing ordering pattern of customers, the 3.7% organic growth in Q3 was a clear positive surprise. The company highlighted that sales and order intake increased sequentially q-o-q. For the fourth quarter, additional sequential growth was indicated not only in absolute terms, but also as organic growth rate. We assume 5% organic growth for...
>Q3 review – beat on EBITDA pre level, guidance confirmed - Merck’s Q3 revenues of € 5,266m (+1.8% y-o-y) were driven by organic growth of 3.8% and were 0%/-1% vs ODDO BHF/consensus. On the bottom line, the company reported EBITDA pre of € 1,618m (+11.9% y-o-y, margin 30.7%), 5% ahead of expectations. EPS pre reached € 2.30, in line with expectations. The 2024 guidance was confirmed with revenues in the range of € 20.7bn to € 22.1bn, trending towards the lower half of...
>Focus on lower capital intensity over the next years - Following some years of elevated capex projects, CFO Helene von Roeder indicated lower capital expenditure in absolute terms that support an improving cash conversion backed also by an improving sales mix. As a result, free cash flow is expected to improve. Regarding the allocation of capital for potential acquisitions, a substantial amount is allocated towards the Life Sciences segment. For Healthcare, a de-risk...
Moody's Ratings (Moody's) has today assigned a Baa2 junior subordinated rating to the proposed €800 million fixed to reset rate notes due 2054 (the hybrid) issued by Merck KGaA (Merck or the company). The outlook is stable. Merck intends to use the proceeds of the new hybrid issuance, for general ...
>Second quarter with strong quarter for Healthcare and Electronics - Merck had already reported, on 26 July, preliminary Q2 results ahead of expectations with revenues of € 5,352m (+0.9% y-o-y). On the bottom line, the company reported EBITDA pre of € 1,509m (-2.9% y-o-y, margin 28.2%). EPS pre reached € 2.20. The company now expects revenues in the range of € 20.7bn to € 22.1bn (previously € 20.6bn to € 22.1bn), which compares to our new forecast of € 21.4bn. On EBIT...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.